Quince Therapeutics, Inc.
QNCX
$0.9905
-$0.0095-0.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.62% | -2.25% | 6.18% | -20.72% | -41.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.00% | 27.35% | 14.36% | -28.09% | -52.03% |
| Operating Income | -37.00% | -27.35% | -14.36% | 28.09% | 52.03% |
| Income Before Tax | -79.66% | -87.93% | -71.85% | 29.45% | 39.20% |
| Income Tax Expenses | 144.16% | 152.82% | 147.58% | 115.41% | 30.63% |
| Earnings from Continuing Operations | -81.07% | -90.06% | -73.63% | 28.37% | 39.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.07% | -90.06% | -73.63% | 28.37% | 39.25% |
| EBIT | -37.00% | -27.35% | -14.36% | 28.09% | 52.03% |
| EBITDA | -38.05% | -25.76% | -13.29% | 28.68% | 52.47% |
| EPS Basic | -56.03% | -59.53% | -48.18% | 38.20% | 47.54% |
| Normalized Basic EPS | -30.90% | -12.15% | 2.37% | 43.19% | 63.22% |
| EPS Diluted | -56.03% | -59.53% | -48.18% | 38.20% | 47.54% |
| Normalized Diluted EPS | -30.90% | -12.15% | 2.37% | 43.19% | 63.22% |
| Average Basic Shares Outstanding | 16.16% | 18.70% | 14.12% | 11.80% | 11.23% |
| Average Diluted Shares Outstanding | 16.16% | 18.70% | 14.12% | 11.80% | 11.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |